Clinical Review: Omega-3 Fatty Acid Addition During Pregnancy

The Clinical Question

Preterm birth (delivery before 37 weeks) remains a leading cause of perinatal mortality and long-term morbidity in children worldwide. While advances in neonatal care have improved survival rates, preventing preterm labour remains a significant obstetric challenge.

Observational data has long suggested a link between diet and gestation length; specifically, communities with high fish consumption, such as the Faroe Islands, often have longer average pregnancies and higher birthweights than populations with low fish intake. This led to the hypothesis that omega-3 long-chain polyunsaturated fatty acids (LCPUFA)—specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)—might influence the biological mechanisms of labour and fetal growth.

The clinical question is straightforward but vital: Does supplementing pregnant women with omega-3 fatty acids (via supplements or diet) reduce the risk of preterm birth and improve neonatal health, and does it confer long-term developmental benefits to the child?

The Approach (Simplified)

This is a Cochrane Systematic Review, widely considered the gold standard for evidence synthesis. The authors searched for all randomized controlled trials (RCTs) assessing omega-3 supplementation during pregnancy up to August 2018.

• The Population: They identified 70 RCTs involving 19,927 women. The studies included women at varying levels of risk—some were healthy low-risk pregnancies, while others included women at high risk for preterm birth, pre-eclampsia, or intrauterine growth restriction.
• The Intervention: The trials compared women taking omega-3 LCPUFA (supplements, fortified foods, or dietary advice) against those taking a placebo or receiving no specific omega-3 intervention.
• The Goal: The primary focus was on birth outcomes (preterm birth, birthweight) and maternal outcomes (pre-eclampsia, depression). They also looked for long-term data on child development (cognition, growth).

Key Findings (The Data)

The review found compelling evidence that omega-3 supplementation influences the timing of birth.

Preterm Birth Reduction The most significant finding was a clear reduction in the risk of giving birth early.

• Preterm Birth (<37 weeks): Women receiving omega-3s had an 11% lower risk of giving birth before 37 weeks compared to the control group (11.9% vs. 13.4%).
• Early Preterm Birth (<34 weeks): The benefit was even more pronounced for early preterm births. The risk was reduced by 42% (2.7% vs. 4.6%).
• Numbers Needed to Treat (NNT): To prevent one early preterm birth (<34 weeks), 52 women need to be treated. To prevent one preterm birth (<37 weeks), the number is 68.

Birthweight and Size Consistent with a longer gestation, babies in the treatment group were generally larger.

• Low Birthweight: There was a 10% reduction in the risk of having a low birthweight baby (<2500g).
• Mean Birthweight: On average, babies in the omega-3 group were about 75g heavier than those in the control group.

The Trade-off: Prolonged Gestation The biological effect of delaying labour appears to work at both ends of the spectrum.

• Post-term Pregnancy: Women taking omega-3s were 61% more likely to have a prolonged pregnancy continuing beyond 42 weeks (2.6% vs. 1.6%). This is a crucial consideration for induction protocols.

Outcomes with No Clear Benefit Despite marketing claims often associating omega-3s with “brain boosting” or maternal mood support, the data was unconvincing in these areas.

• Child Cognition/Development: The review found very few differences between groups regarding child IQ, cognition, language, or motor skills.
• Maternal Mental Health: There was insufficient evidence to determine if omega-3s prevent postnatal depression.
• Pre-eclampsia: There was a possible reduction in pre-eclampsia risk, but the quality of evidence was low, and sensitivity analyses (removing lower-quality studies) suggested no difference.

Strengths & Limitations

Strengths

• High-Quality Evidence: The findings regarding preterm and early preterm birth are graded as “high-quality” evidence. The sample size is massive (nearly 20,000 women), and the sensitivity analyses largely confirmed the main results.
• Clinical Relevance: The primary outcomes (preterm birth) are objective and clinically critical, minimizing the risk of reporting bias influencing the core conclusion.

Limitations

• Heterogeneity: The included studies used different types of omega-3 (fish oil vs. algal oil), different doses (ranging from <500mg to >1g), and started at different times in pregnancy. While subgroup analyses did not show massive differences, the “optimal” dose remains somewhat open to interpretation.
• Long-term Follow-up: While birth outcomes were well-reported, data on long-term child outcomes (like neurodevelopment) suffered from attrition bias (participants dropping out over time) and inconsistent measurement methods, making these conclusions less certain.
• Side Effects: While serious adverse events were rare, minor issues like “belching” and “unpleasant taste” were more common in the treatment group, which could affect adherence in real-world practice.

The Bottom Line

Omega-3 LCPUFA supplementation during pregnancy is an effective, evidence-based strategy for preventing preterm birth, particularly early preterm birth (<34 weeks). The intervention is relatively low-cost and safe. However, clinicians should be aware that this prolongation of pregnancy carries a trade-off: an increased risk of post-term gestation (>42 weeks), which may necessitate induction. Current evidence does not support the routine use of omega-3s for the primary purpose of improving child cognitive development or preventing maternal depression.